Climb Historical Balance Sheet
| CLYM Stock | 1.95 0.08 3.94% |
Trend analysis of Climb Bio balance sheet accounts such as Other Current Liab of 118 K, Total Current Liabilities of 3.6 M or Total Stockholder Equity of 116.9 M provides information on Climb Bio's total assets, liabilities, and equity, which is the actual value of Climb Bio to its prevalent stockholders. By breaking down trends over time using Climb Bio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Climb |
About Climb Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Climb Bio at a specified time, usually calculated after every quarter, six months, or one year. Climb Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Climb Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Climb currently owns. An asset can also be divided into two categories, current and non-current.
Climb Bio Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Climb Bio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Climb Bio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Accounts Payable
An accounting item on the balance sheet that represents Climb Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Climb Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Cash
Cash refers to the most liquid asset of Climb Bio, which is listed under current asset account on Climb Bio balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Climb Bio customers. The amounts must be unrestricted with restricted cash listed in a different Climb Bio account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most accounts from Climb Bio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Climb Bio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.At this time, Climb Bio's Total Current Assets are very stable compared to the past year. As of the 21st of December 2024, Net Working Capital is likely to grow to about 109.1 M, while Accounts Payable is likely to drop about 62.7 K.
| 2021 | 2023 | 2024 (projected) | Other Current Liabilities | 138K | 124.2K | 118.0K | Total Assets | 173.2M | 110.5M | 121.9M |
Climb Bio balance sheet Correlations
Click cells to compare fundamentals
Climb Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.